|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000180758 |
Summary for GPR157 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000180758 | Gene symbol | GPR157 |
| Gene name | G protein-coupled receptor 157 | |
| HGNC | 23687 | |
| Entrez ID | 80045 | |
| Gene type | protein_coding | |
| Synonyms | GPR157|FLJ12132 | |
| UniProtAcc | Q5UAW9 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for GPR157 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| GPR157 | 1.37e+03 | -1.01e+00 | 2.15e-01 | -4.69e+00 | 2.72e-06 | 1.41e-05 | STAD |
| GPR157 | 2.96e+03 | 1.31e+00 | 3.79e-01 | 3.45e+00 | 5.54e-04 | 3.96e-03 | ESCA |
| GPR157 | 3.92e+02 | -1.01e+00 | 2.59e-01 | -3.89e+00 | 9.96e-05 | 4.37e-04 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| GPR157 | 9.83e+02 | 1.05e+00 | 2.72e-01 | 3.87e+00 | 1.08e-04 | 2.85e-04 | KICH |
| GPR157 | 1.10e+03 | 1.63e+00 | 2.81e-01 | 5.80e+00 | 6.74e-09 | 1.13e-07 | READ |
Top |
Sex-biased somatic mutation for GPR157 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for GPR157 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| DLBC | cg18040436 | chr1:9129253 | CGI:chr1:9128444-9129417 | promoter | 2.50e-01 | 1.16e-01 | 2.98e+00 | 2.89e-03 | 8.77e-03 | 1.35e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRP | cg17940013 | chr1:9128629 | CGI:chr1:9128444-9129417 | promoter,gene body | 1.16e-01 | 2.23e-01 | -6.21e+00 | 5.23e-10 | 5.01e-08 | -1.07e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
Top |
Exon skipping events with PSI in TCGA for GPR157 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| ESCA | exon_skip_21603 | 6.32e-01 | 7.36e-01 | -2.58e+00 | 9.78e-03 | 2.42e-02 | -1.04e-01 |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for GPR157 |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| KIRC | GPR157-002 | chr1_9102303_- | 2.53e-01 | 3.03e-01 | -2.57e+00 | 1.01e-02 | 4.20e-02 | -5.00e-02 |
| KIRC | GPR157-002 | chr1_9103037_- | 2.69e-01 | 1.68e-01 | 2.14e+00 | 3.24e-02 | 4.78e-02 | 1.01e-01 |
| KIRC | GPR157-002 | chr1_9103443_- | 2.54e-01 | 1.53e-01 | 2.77e+00 | 5.55e-03 | 4.08e-02 | 1.01e-01 |
| LUAD | GPR157-002 | chr1_9102348_- | 2.00e-01 | 1.43e-01 | 2.18e+00 | 2.89e-02 | 4.22e-02 | 5.67e-02 |
| LUAD | GPR157-002 | chr1_9102944_- | 1.29e-01 | 1.71e-01 | -3.28e+00 | 1.05e-03 | 1.92e-02 | -4.22e-02 |
| THCA | GPR157-002 | chr1_9101019_- | 2.17e-01 | 1.56e-01 | 2.11e+00 | 3.48e-02 | 4.91e-02 | 6.10e-02 |
| HNSC | GPR157-002 | chr1_9100841_- | 3.69e-01 | 4.05e-01 | -2.60e+00 | 9.28e-03 | 3.57e-02 | -3.61e-02 |
| HNSC | GPR157-002 | chr1_9101144_- | 4.15e-01 | 4.63e-01 | -2.19e+00 | 2.84e-02 | 4.41e-02 | -4.88e-02 |
| HNSC | GPR157-002 | chr1_9101180_- | 1.46e-01 | 1.11e-01 | 2.27e+00 | 2.30e-02 | 4.33e-02 | 3.47e-02 |
| HNSC | GPR157-002 | chr1_9101186_- | 6.49e-01 | 6.84e-01 | -2.23e+00 | 2.61e-02 | 4.41e-02 | -3.49e-02 |
| HNSC | GPR157-002 | chr1_9101235_- | 1.75e-01 | 1.24e-01 | 2.44e+00 | 1.45e-02 | 3.96e-02 | 5.05e-02 |
| HNSC | GPR157-002 | chr1_9101599_- | 1.77e-01 | 1.23e-01 | 2.21e+00 | 2.74e-02 | 4.41e-02 | 5.35e-02 |
| LUSC | GPR157-002 | chr1_9103260_- | 1.56e-01 | 1.97e-01 | -2.76e+00 | 5.81e-03 | 4.91e-02 | -4.10e-02 |
| SKCM | GPR157-002 | chr1_9101133_- | 4.01e-01 | 2.68e-01 | 2.39e+00 | 1.68e-02 | 4.90e-02 | 1.33e-01 |
| SKCM | GPR157-002 | chr1_9102247_- | 2.58e-01 | 3.71e-01 | -2.00e+00 | 4.52e-02 | 4.90e-02 | -1.14e-01 |
| SKCM | GPR157-002 | chr1_9103328_- | 3.73e-01 | 3.03e-01 | 2.08e+00 | 3.79e-02 | 4.90e-02 | 6.96e-02 |
| COAD | GPR157-002 | chr1_9100841_- | 3.04e-01 | 2.72e-01 | 2.15e+00 | 3.18e-02 | 4.10e-02 | 3.17e-02 |
| COAD | GPR157-002 | chr1_9100917_- | 1.74e-01 | 2.31e-01 | -2.47e+00 | 1.37e-02 | 2.68e-02 | -5.70e-02 |
| COAD | GPR157-002 | chr1_9102147_- | 2.49e-01 | 2.05e-01 | 2.37e+00 | 1.78e-02 | 3.09e-02 | 4.36e-02 |
| COAD | GPR157-002 | chr1_9102247_- | 2.59e-01 | 2.03e-01 | 2.16e+00 | 3.08e-02 | 4.03e-02 | 5.62e-02 |
| COAD | GPR157-002 | chr1_9103443_- | 2.45e-01 | 1.77e-01 | 2.49e+00 | 1.26e-02 | 2.55e-02 | 6.75e-02 |
| BLCA | GPR157-002 | chr1_9103260_- | 1.48e-01 | 1.98e-01 | -2.13e+00 | 3.29e-02 | 4.98e-02 | -5.01e-02 |
| STAD | GPR157-002 | chr1_9100916_- | 3.02e-01 | 3.33e-01 | -2.06e+00 | 3.93e-02 | 4.96e-02 | -3.09e-02 |
| STAD | GPR157-002 | chr1_9102147_- | 2.59e-01 | 3.41e-01 | -2.71e+00 | 6.69e-03 | 4.96e-02 | -8.19e-02 |
| LIHC | GPR157-002 | chr1_9102289_- | 4.24e-01 | 3.32e-01 | 2.31e+00 | 2.10e-02 | 4.43e-02 | 9.15e-02 |
| KIRP | GPR157-002 | chr1_9100917_- | 3.06e-01 | 1.83e-01 | 2.13e+00 | 3.29e-02 | 4.72e-02 | 1.23e-01 |
| SARC | GPR157-002 | chr1_9102303_- | 2.52e-01 | 3.47e-01 | -2.24e+00 | 2.52e-02 | 4.85e-02 | -9.57e-02 |
| PAAD | GPR157-002 | chr1_9101140_- | 5.30e-01 | 3.78e-01 | 2.44e+00 | 1.45e-02 | 4.66e-02 | 1.52e-01 |
| READ | GPR157-002 | chr1_9102165_- | 3.58e-01 | 2.84e-01 | 1.97e+00 | 4.89e-02 | 4.94e-02 | 7.35e-02 |
| READ | GPR157-002 | chr1_9103328_- | 3.84e-01 | 2.91e-01 | 2.61e+00 | 8.98e-03 | 4.67e-02 | 9.27e-02 |
| MESO | GPR157-002 | chr1_9100841_- | 4.36e-01 | 2.64e-01 | 2.64e+00 | 8.36e-03 | 4.83e-02 | 1.72e-01 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| KIRC | GPR157-002 | chr1_9102335_- | 3.19e-01 | 3.60e-01 | -2.14e+00 | 3.20e-02 | 3.79e-02 | -4.14e-02 |
| LUAD | GPR157-002 | chr1_9101078_- | 1.88e-01 | 2.45e-01 | -2.19e+00 | 2.86e-02 | 3.61e-02 | -5.72e-02 |
| LUAD | GPR157-002 | chr1_9102303_- | 2.73e-01 | 2.08e-01 | 2.01e+00 | 4.43e-02 | 4.69e-02 | 6.46e-02 |
| THCA | GPR157-002 | chr1_9100930_- | 2.74e-01 | 1.75e-01 | 2.38e+00 | 1.71e-02 | 2.60e-02 | 9.89e-02 |
| HNSC | GPR157-002 | chr1_9100930_- | 2.42e-01 | 1.34e-01 | 2.98e+00 | 2.90e-03 | 5.20e-03 | 1.08e-01 |
| HNSC | GPR157-002 | chr1_9102164_- | 2.74e-01 | 1.57e-01 | 3.19e+00 | 1.43e-03 | 3.00e-03 | 1.18e-01 |
| HNSC | GPR157-002 | chr1_9102397_- | 2.22e-01 | 1.53e-01 | 2.30e+00 | 2.15e-02 | 2.61e-02 | 6.85e-02 |
| LUSC | GPR157-002 | chr1_9100841_- | 3.70e-01 | 2.93e-01 | 2.31e+00 | 2.11e-02 | 2.99e-02 | 7.73e-02 |
| LUSC | GPR157-002 | chr1_9100899_- | 2.83e-01 | 2.25e-01 | 2.40e+00 | 1.65e-02 | 2.61e-02 | 5.79e-02 |
| LUSC | GPR157-002 | chr1_9100916_- | 2.32e-01 | 1.64e-01 | 3.18e+00 | 1.49e-03 | 6.19e-03 | 6.75e-02 |
| LUSC | GPR157-002 | chr1_9101186_- | 6.50e-01 | 5.42e-01 | 3.26e+00 | 1.13e-03 | 5.18e-03 | 1.08e-01 |
| LUSC | GPR157-002 | chr1_9102289_- | 2.88e-01 | 2.25e-01 | 2.60e+00 | 9.41e-03 | 1.88e-02 | 6.30e-02 |
| LUSC | GPR157-002 | chr1_9102335_- | 3.76e-01 | 3.07e-01 | 2.81e+00 | 4.93e-03 | 1.26e-02 | 6.98e-02 |
| LUSC | GPR157-002 | chr1_9103328_- | 3.56e-01 | 2.71e-01 | 2.99e+00 | 2.82e-03 | 8.85e-03 | 8.41e-02 |
| STAD | GPR157-002 | chr1_9100899_- | 3.62e-01 | 2.67e-01 | 2.17e+00 | 2.98e-02 | 3.91e-02 | 9.51e-02 |
| STAD | GPR157-002 | chr1_9100916_- | 3.02e-01 | 2.27e-01 | 1.98e+00 | 4.72e-02 | 4.87e-02 | 7.50e-02 |
| STAD | GPR157-002 | chr1_9100930_- | 4.42e-01 | 2.62e-01 | 3.18e+00 | 1.46e-03 | 1.01e-02 | 1.80e-01 |
| STAD | GPR157-002 | chr1_9101133_- | 4.62e-01 | 3.12e-01 | 2.32e+00 | 2.01e-02 | 3.27e-02 | 1.49e-01 |
| STAD | GPR157-002 | chr1_9101140_- | 6.89e-01 | 5.11e-01 | 2.63e+00 | 8.53e-03 | 2.19e-02 | 1.78e-01 |
| STAD | GPR157-002 | chr1_9101186_- | 6.95e-01 | 5.16e-01 | 2.73e+00 | 6.41e-03 | 1.91e-02 | 1.78e-01 |
| STAD | GPR157-002 | chr1_9102165_- | 4.53e-01 | 2.85e-01 | 2.27e+00 | 2.33e-02 | 3.53e-02 | 1.68e-01 |
| STAD | GPR157-002 | chr1_9102193_- | 3.58e-01 | 2.20e-01 | 2.09e+00 | 3.69e-02 | 4.37e-02 | 1.38e-01 |
| ESCA | GPR157-002 | chr1_9100841_- | 4.33e-01 | 2.79e-01 | 2.06e+00 | 3.97e-02 | 4.33e-02 | 1.54e-01 |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| BRCA | GPR157-002 | chr1_9100841_- | 4.13e-01 | 2.06e-01 | 9.78e+00 | 1.41e-22 | 5.08e-21 | 2.07e-01 |
| BRCA | GPR157-002 | chr1_9100899_- | 2.93e-01 | 1.69e-01 | 6.95e+00 | 3.75e-12 | 3.28e-11 | 1.24e-01 |
| BRCA | GPR157-002 | chr1_9100916_- | 2.53e-01 | 1.75e-01 | 4.71e+00 | 2.45e-06 | 8.60e-06 | 7.85e-02 |
| BRCA | GPR157-002 | chr1_9100917_- | 2.23e-01 | 1.54e-01 | 2.57e+00 | 1.01e-02 | 1.41e-02 | 6.85e-02 |
| BRCA | GPR157-002 | chr1_9100930_- | 2.95e-01 | 2.17e-01 | 4.34e+00 | 1.40e-05 | 4.23e-05 | 7.81e-02 |
| BRCA | GPR157-002 | chr1_9101140_- | 5.33e-01 | 3.94e-01 | 2.64e+00 | 8.32e-03 | 1.20e-02 | 1.39e-01 |
| BRCA | GPR157-002 | chr1_9101144_- | 4.96e-01 | 3.74e-01 | 2.48e+00 | 1.30e-02 | 1.73e-02 | 1.22e-01 |
| BRCA | GPR157-002 | chr1_9101159_- | 4.54e-01 | 2.92e-01 | 5.16e+00 | 2.42e-07 | 1.01e-06 | 1.62e-01 |
| BRCA | GPR157-002 | chr1_9101186_- | 6.95e-01 | 4.28e-01 | 1.15e+01 | 2.31e-30 | 2.64e-28 | 2.67e-01 |
| BRCA | GPR157-002 | chr1_9102165_- | 3.99e-01 | 2.94e-01 | 3.22e+00 | 1.28e-03 | 2.41e-03 | 1.05e-01 |
| BRCA | GPR157-002 | chr1_9102244_- | 3.56e-01 | 2.69e-01 | 2.37e+00 | 1.79e-02 | 2.24e-02 | 8.73e-02 |
| BRCA | GPR157-002 | chr1_9102289_- | 3.03e-01 | 2.02e-01 | 5.45e+00 | 5.04e-08 | 2.38e-07 | 1.01e-01 |
| BRCA | GPR157-002 | chr1_9102303_- | 2.77e-01 | 2.17e-01 | 4.38e+00 | 1.20e-05 | 3.69e-05 | 6.07e-02 |
| BRCA | GPR157-002 | chr1_9102335_- | 3.74e-01 | 3.48e-01 | 1.99e+00 | 4.64e-02 | 4.73e-02 | 2.62e-02 |
| BRCA | GPR157-002 | chr1_9103275_- | 2.20e-01 | 1.82e-01 | 2.54e+00 | 1.12e-02 | 1.53e-02 | 3.80e-02 |
| BRCA | GPR157-002 | chr1_9103328_- | 3.77e-01 | 3.29e-01 | 2.00e+00 | 4.53e-02 | 4.63e-02 | 4.78e-02 |
| LUAD | GPR157-002 | chr1_9102335_- | 3.56e-01 | 2.82e-01 | 2.26e+00 | 2.39e-02 | 3.16e-02 | 7.42e-02 |
| THCA | GPR157-002 | chr1_9100899_- | 2.78e-01 | 2.13e-01 | 3.00e+00 | 2.66e-03 | 6.88e-03 | 6.49e-02 |
| HNSC | GPR157-002 | chr1_9100916_- | 2.16e-01 | 1.47e-01 | 2.22e+00 | 2.65e-02 | 3.22e-02 | 6.90e-02 |
| LUSC | GPR157-002 | chr1_9102165_- | 4.59e-01 | 2.72e-01 | 2.43e+00 | 1.52e-02 | 2.83e-02 | 1.87e-01 |
| COAD | GPR157-002 | chr1_9101186_- | 5.40e-01 | 4.05e-01 | 2.09e+00 | 3.65e-02 | 4.13e-02 | 1.35e-01 |
| BLCA | GPR157-002 | chr1_9100841_- | 3.86e-01 | 2.14e-01 | 2.77e+00 | 5.52e-03 | 3.32e-02 | 1.72e-01 |
| BLCA | GPR157-002 | chr1_9101137_- | 3.70e-01 | 2.30e-01 | 2.49e+00 | 1.29e-02 | 3.38e-02 | 1.41e-01 |
| LIHC | GPR157-002 | chr1_9102289_- | 3.32e-01 | 4.69e-01 | -2.27e+00 | 2.33e-02 | 3.97e-02 | -1.37e-01 |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for GPR157 |
| TFs related to GPR157. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BLCA | ZNF28 | GPR157 | 4.03e+00 | 9.82e-01 | 2.83e+00 | 2.40e-03 | Male-biased |
| BLCA | ZNF682 | GPR157 | 4.01e+00 | 9.81e-01 | 2.83e+00 | 2.59e-03 | Male-biased |
| GPR157 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for GPR157 |
| RBPs related to ES in GPR157. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| GPR157 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000180758 | AL136982.6,hsa-mir-373,GPR157 | Male-specific ceRNA | TCGA-STAD |
| ENSG00000180758 | LINC01395,hsa-mir-373,GPR157 | Male-specific ceRNA | TCGA-STAD |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs61771056 | chr1:16022841:C:T | - | 0.229199849231219 | 0.0168133890000185 | HNSC | Female-baised eQTL |
| rs221035 | chr1:16200034:G:A | - | -0.122368795690043 | 0.0498845149143609 | HNSC | Female-baised eQTL |
| rs10915298 | chr1:4952241:G:A | - | 0.192131980678121 | 0.000247774044678762 | LUSC | Female-baised eQTL |
| rs78856887 | chr1:4953497:G:A | - | 0.192131980678121 | 0.000247774044678762 | LUSC | Female-baised eQTL |
| rs75465543 | chr1:4953501:T:A | - | 0.192131980678121 | 0.000247774044678762 | LUSC | Female-baised eQTL |
| rs182698541 | chr1:9933301:T:C | - | 0.154891191686351 | 0.0038368691302027 | LUSC | Female-baised eQTL |
| rs3121822 | chr1:2041023:T:C | - | 0.119115544340966 | 0.00400042921369505 | LUSC | Female-baised eQTL |
| rs185253044 | chr1:6401029:A:G | - | 0.152801248297826 | 0.00940163153411751 | LUSC | Female-baised eQTL |
| rs60915457 | chr1:6366874:G:A | - | 0.129666414456056 | 0.0148029970876676 | LUSC | Female-baised eQTL |
| rs146870752 | chr1:6378982:G:A | - | 0.129666414456056 | 0.0148029970876676 | LUSC | Female-baised eQTL |
| rs56292643 | chr1:6365699:C:T | - | 0.133654521052582 | 0.0289879530178171 | LUSC | Female-baised eQTL |
| rs112539520 | chr1:6365955:C:T | - | 0.117865973321104 | 0.0326244695631344 | LUSC | Female-baised eQTL |
| rs111774890 | chr1:6366748:C:T | - | 0.117865973321104 | 0.0326244695631344 | LUSC | Female-baised eQTL |
| rs55702497 | chr1:6368035:G:A | - | 0.117865973321104 | 0.0326244695631344 | LUSC | Female-baised eQTL |
| rs77335497 | chr1:6370369:C:A | - | 0.117865973321104 | 0.0326244695631344 | LUSC | Female-baised eQTL |
| rs74049523 | chr1:6281732:G:A | - | 0.112860639311795 | 0.0445453408194467 | LUSC | Female-baised eQTL |
| rs2501776 | chr1:17292784:C:T | - | -0.0706118642939385 | 0.0434386842869846 | STAD | Female-baised eQTL |
| rs11812067 | chr1:15246089:C:T | - | 0.0986666837019674 | 0.000864451880269592 | KIRC | Female-baised eQTL |
| rs12049516 | chr1:15245889:C:T | - | 0.0936376454951919 | 0.000965816065214081 | KIRC | Female-baised eQTL |
| rs3753325 | chr1:15251119:C:T | - | 0.0877139279990184 | 0.00331793569528938 | KIRC | Female-baised eQTL |
| rs57175514 | chr1:15252408:A:G | - | 0.0874463049478639 | 0.00357751588126742 | KIRC | Female-baised eQTL |
| rs1952295 | chr1:15255337:T:C | - | 0.0832693679369462 | 0.00734186738756022 | KIRC | Female-baised eQTL |
| rs55704135 | chr1:10134381:G:A | - | 0.0981475018858557 | 0.0301383871371842 | KIRC | Female-baised eQTL |
| rs12239770 | chr1:4718798:T:C | - | 0.109574657770728 | 0.0353666644275843 | KIRC | Female-baised eQTL |
| rs9783085 | chr1:2925430:G:A | - | -0.0807333305787408 | 0.0284640220436577 | COAD | Female-baised eQTL |
| rs34512080 | chr1:2925918:C:T | - | -0.0807333305787408 | 0.0284640220436577 | COAD | Female-baised eQTL |
| rs12063994 | chr1:2926499:T:C | - | -0.0807333305787408 | 0.0284640220436577 | COAD | Female-baised eQTL |
| rs4648436 | chr1:2927285:G:A | - | -0.0807333305787408 | 0.0284640220436577 | COAD | Female-baised eQTL |
| rs4648437 | chr1:2927502:A:G | - | -0.0807333305787408 | 0.0284640220436577 | COAD | Female-baised eQTL |
| rs12062218 | chr1:2924766:T:C | - | -0.0812768175756175 | 0.0299285073218572 | COAD | Female-baised eQTL |
| rs10797363 | chr1:2926182:A:C | - | -0.0803565872196734 | 0.0302714834251339 | COAD | Female-baised eQTL |
| rs10752730 | chr1:2927809:T:G | - | -0.0803052314122337 | 0.0305124884253426 | COAD | Female-baised eQTL |
| rs10797367 | chr1:2929187:C:T | - | -0.0784573261101706 | 0.0411454104381983 | COAD | Female-baised eQTL |
| rs2045331 | chr1:2925705:G:A | - | -0.0774277545825249 | 0.0418508440014945 | COAD | Female-baised eQTL |
| rs9782915 | chr1:2925315:A:G | - | -0.0779684317343002 | 0.0429627694205743 | COAD | Female-baised eQTL |
| rs4648354 | chr1:2929076:G:T | - | -0.0774362339301778 | 0.0476360425381252 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs11586437 | chr1:16257999:A:T | - | 0.0991783963492774 | 0.000615261760325432 | KIRP | Male-baised eQTL |
| rs114935144 | chr1:16263744:A:C | - | 0.087670232911546 | 0.00275529105178177 | KIRP | Male-baised eQTL |
| rs72856437 | chr1:3039178:C:T | - | 0.0857861667172947 | 0.00297240791049224 | KIRP | Male-baised eQTL |
| rs6603851 | chr1:16299655:A:T | - | 0.0812712804763035 | 0.00739869401217016 | KIRP | Male-baised eQTL |
| rs6693685 | chr1:14038833:A:T | - | 0.0826539389378917 | 0.0088674601014557 | KIRP | Male-baised eQTL |
| rs11808276 | chr1:3305906:C:T | - | 0.0691424656225288 | 0.0126238654197622 | KIRP | Male-baised eQTL |
| rs223165 | chr1:18301218:C:T | - | 0.0809178107410207 | 0.0130943854013494 | KIRP | Male-baised eQTL |
| rs11260968 | chr1:18077363:T:C | - | 0.0676272953765905 | 0.02353013722072 | KIRP | Male-baised eQTL |
| rs12075981 | chr1:18077638:C:T | - | 0.0676272953765905 | 0.02353013722072 | KIRP | Male-baised eQTL |
| rs13375075 | chr1:3558213:A:C | - | 0.0743246921179275 | 0.0258807217041077 | KIRP | Male-baised eQTL |
| rs10492993 | chr1:18077685:T:C | - | 0.0655249814084652 | 0.0311883769744003 | KIRP | Male-baised eQTL |
| rs60197443 | chr1:4380852:C:T | - | 0.0629300247114396 | 0.0345423352340884 | KIRP | Male-baised eQTL |
| rs59971856 | chr1:4380855:A:G | - | 0.0629300247114396 | 0.0345423352340884 | KIRP | Male-baised eQTL |
| rs61771908 | chr1:14462332:T:C | - | 0.0413495285379489 | 0.00201590930956805 | KIRC | Male-baised eQTL |
| rs12564154 | chr1:14463039:C:T | - | 0.0413495285379489 | 0.00201590930956805 | KIRC | Male-baised eQTL |
| rs35788652 | chr1:14463483:A:G | - | 0.0413495285379489 | 0.00201590930956805 | KIRC | Male-baised eQTL |
| rs12116420 | chr1:14463579:T:C | - | 0.0413495285379489 | 0.00201590930956805 | KIRC | Male-baised eQTL |
| rs12119122 | chr1:14463936:G:C | - | 0.0396184693233446 | 0.00327664316774423 | KIRC | Male-baised eQTL |
| rs12130603 | chr1:14418293:C:G | - | 0.0359980043691128 | 0.0330616862497801 | KIRC | Male-baised eQTL |
| rs10927439 | chr1:14461622:C:G | - | 0.031633953530908 | 0.0389938175214093 | KIRC | Male-baised eQTL |
| rs12119451 | chr1:14418095:A:G | - | 0.0348524678273774 | 0.0486527727278545 | KIRC | Male-baised eQTL |
| rs115189622 | chr1:11948599:A:G | - | 0.0958253619960556 | 0.0269638741283655 | COAD | Male-baised eQTL |
| rs116652082 | chr1:11948601:G:A | - | 0.0958253619960556 | 0.0269638741283655 | COAD | Male-baised eQTL |
| rs2336380 | chr1:11948840:G:C | - | 0.0958253619960556 | 0.0269638741283655 | COAD | Male-baised eQTL |
| rs2336381 | chr1:11948967:A:G | - | 0.0958253619960556 | 0.0269638741283655 | COAD | Male-baised eQTL |
| rs72640301 | chr1:11945193:G:A | - | 0.094396041274445 | 0.0316602817357715 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000180758 |
| CpG Site: cg19863456 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.477996150785633 | |
 | Gene ID: ENSG00000180758 |
| CpG Site: cg19863456 | |
| Position to Gene: gene | |
| Male Effect: -0.430954498099071 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg19863456 | chr1:9125942 | gene | -0.430954498099071 | 5.15359096669554e-10 | -0.4915275078306518 | 7.234609382395716e-14 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg19863456 | chr1:9125942 | gene | -0.477996150785633 | 1.59023232683194e-29 | -0.9409112773590269 | 9.549711684159952e-33 | KIRP |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of GPR157 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
